Sue Desmond-Hellmann is an American oncologist and biotechnology leader who served as the Chief Executive Officer of the Bill & Melinda Gates Foundation from 2014–2020. She was previously Chancellor of the University of California, San Francisco (UCSF), the first woman to hold the position, and Arthur and Toni Rembe Rock Distinguished Professor, and before that president of product development at Genentech, where she played a role in the development of the first gene-targeted cancer drugs, Avastin and Herceptin.
Early life and education
Desmond-Hellmann grew up in Reno, Nevada, as one of seven children. Her father worked as a pharmacist and her mother was an English teacher. She earned a bachelor of science degree in pre-medicine and an M.D. from the University of Nevada, Reno and received her residency training at UCSF, where she served as chief resident. She is board-certified in internal medicine and medical oncology, and also holds a master's degree in public health from the University of California, Berkeley School of Public Health.
Career
Beginnings
Desmond-Hellmann served as an associate adjunct professor of epidemiology and biostatistics At UCSF. She joined the UCSF medical faculty during the HIV/AIDS epidemic in San Francisco, and worked on Kaposi's sarcoma. Beginning in 1989 both she and her husband, an infectious disease doctor, spent two years as visiting faculty at the Uganda Cancer Institute, studying and treating patients with infectious diseases and Kaposi's sarcoma in a project funded by the Rockefeller Foundation. She then spent two years in private practice.
Returning to clinical research, Desmond-Hellmann became associate director of clinical cancer research at Bristol-Myers Squibb Pharmaceutical Research Institute. While there, she was the project team leader for Taxol.
In 1995 Desmond-Hellmann joined Genentech as a clinical scientist. She was named chief medical officer the following year, and in 1999 became executive vice president of development and product operations. From March 2004 through April 2009 she was president of product development, playing a role in the development of two of the first gene-targeted therapies for cancer, Avastin and Herceptin. She left after the company was acquired by Roche Pharmaceuticals. At that point her compensation was $8 million a year.
From 2005 to 2008, Desmond-Hellmann served a three-year term as a member of the American Association for Cancer Research board of directors, and from 2001 to 2009, she served on the executive committee of the board of directors of the Biotechnology Industry Organization. She also served a three-year term on the Economic Advisory Council of the Federal Reserve Bank of San Francisco beginning in January 2009. She served on the corporate board of Affymetrix from 2004 to 2009 and on the board of Procter & Gamble in 2012–13,
Chancellor of UCSF, 2009–2013
After being invited to apply, on August 3, 2009, Desmond-Hellmann became the ninth Chancellor of UCSF, and the first woman to hold the position. Desmond-Hellmann became the first Chancellor drawn from outside academia. Her starting salary was $450,000 a year.
In June 2010, one day after being questioned by The New York Times, Desmond-Hellmann sold her stock in the Altria Group, which owns Phillip Morris USA and other tobacco companies, and subsequently donated $134,000 to the tobacco control center at UCSF. She said that many of her holdings had been purchased on her behalf by her stockbroker and that she was too busy to oversee all her investments, although she had included the stock on her financial disclosure statement.
In January 2012 Desmond-Hellmann proposed changing the relationship between UCSF, a health sciences university, and the University of California. She proposed creating partnerships between UCSF and private pharmaceutical corporations and other sources of funding, in order to increase its revenues and resolve its projected financial instability.
Desmond-Hellmann served as UCSF Chancellor until March 2014, holding the Arthur and Toni Rembe Rock Distinguished Professorship during her tenure.